Trial Profile

A Two-part Open Label Study of the Pharmacodynamic Effects of Intranasal Nalmefene Compared to Intranasal Naloxone in Healthy Volunteers Under Steady State Opioid Agonism

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nalmefene (Primary) ; Naloxone
Indications Opioid-related disorders
Focus Pharmacodynamics; Registrational
Sponsors Opiant Pharmaceuticals

Most Recent Events

11 Mar 2024 According to an Indivior media release, this study was a part of the OPVEE development program and reviewed by the FDA as part of the approval process. The data was collected at the primary endpoint in 50 subjects.
11 Mar 2024 Primary endpoint has been met. (Change in minute ventilation) , according to Results published in an Indivior media release
11 Mar 2024 Results published in an Indivior media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com